13 Jun Drug Patent Seizures Put American Innovation at Needless Risk
Karen Kerrigan
RealClearHealth, 6/13/2022
...
Author: Bayh-Dole Coalition
07 Jun Revoking drug patents will cost Californians their lives and San Francisco biotech startups their motivation
Howard Dean
San Francisco Examiner, 6/7/2022...
31 May DOE’s Misuse of Bayh-Dole’s ‘Exceptional Circumstances’ Provision: How Uniform Patent Policies Slip Away
Joseph Allen
IPWatchdog, 5/26/2022 ...
26 May Using Bayh-Dole for cancer drug march-in rights is wrong
David Kappos
Law360, 5/25/2022 ...
26 May Prostate Drug Price Controls Come at Too High a Cost
Craig Garthwaite
RealClearPolicy, 5/26/2022 ...
25 Apr Blockbuster cancer drug developed by Bay Area biotech at center of drug-pricing ‘march-in’ rights controversy
Ron Leuty
San Francisco Business Times, 4/22/2022 ...
07 Apr US universities fight potential Biden move on drug patents
Paul Basken
Times Higher Education, 4/7/2022
...
07 Apr $150K Prostate Cancer Drug Draws New Attention to ‘March-In’ Rights
Jennifer Henderson
MedPage Today, 4/6/2022 ...
06 Apr Removing patent rights to lower drug costs is dangerous precedent
Walter G. Copan
Denver Post, 4/6/2022 ...